XZO CEO buys daily as Q1 results land

XZO heads into the post-earnings week with a single standout: its own CEO has been buying the stock every single trading day for nearly two weeks.

CEO Paresh Patel — who is also Chairman and holds roughly 1.8% of the company through these accumulating purchases — bought shares on each of the ten most recent trading sessions visible in the data. The purchases ranged from roughly 2,000 shares a day through April into early May. Total net buying over the past 90 days runs to 48,000 shares, worth approximately $764,000. The price paid has crept upward across those sessions, from $15.91 on April 30 to $16.61 as recently as May 4. Tuesday, the stock closed at $17.25, meaning those recent lots are already in the green.

The earnings context gives the CEO's buying some additional framing. Exzeo reported Q1 results on May 6. EPS of $0.22 beat the $0.21 estimate. Revenue of $55.5 million missed the $58.1 million consensus. Parent company HCI — which holds 82.5% of XZO — beat on both lines in its own Q1, posting EPS of $5.45 against a $4.96 estimate on revenue of $242.9 million. The prior two earnings events for XZO both produced positive immediate reactions: the February prints generated a 5.2% and 9.0% one-day move respectively. It is too early to read a full post-earnings reaction for the May 6 release.

Short interest is low and not the story here. SI stands at just 0.65% of the free float — barely a rounding error for most shorts-focused investors. That said, the weekly trajectory is worth noting for context: SI jumped 25% week-on-week before pulling back 5.7% on May 5 alone, a volatile pattern in a very thinly borrowed stock. Borrowing costs remain cheap at 0.70% APR, up 38% on the week but still well within normal range. Availability in the lending market is ample, with utilization at just 17% against a 52-week high of 40% — far from any squeeze dynamic.

Analyst coverage is sparse and dated. Three firms initiated coverage in December 2025 — William Blair with an Outperform, Truist Securities with a Buy and a $25 target, and Citizens with a Market Outperform and a $27 target. The mean target at that time was $26. Given the stock has moved materially since then, those targets should be treated with caution rather than taken as current guidance. No fresh analyst actions have emerged around this earnings print.

The ORTEX short score of 43.9 is moderate and has drifted in a narrow band since mid-April, reflecting neither escalating bearish conviction nor any collapse. Institutional ownership outside the HCI parent is thin — the next largest disclosed holder is Ophir Asset Management with just over 1%, while Janus Henderson, Jennison, Driehaus, and Goldman Sachs Asset Management all entered positions as new buyers in recent filings. The stock has gained 21% over the past month.

The next variable to watch is whether Q1's revenue miss prompts any Street reaction — or whether the CEO's steady open-market buying programme signals something the market hasn't yet priced.